Program
Berzanoflast
Also written as “AZD4144”, “[14C]AZD4144 Solution for Infusion” and “[14C]AZD4144 Oral Solution”.
Its studies are mostly in Sepsis · Kidney Failure, Chronic · Renal Insufficiency, Chronic · Atherosclerosis · Inflammation, led by AstraZeneca.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 112 open or running | phase 2since Oct 8, 2025 | Nov 3, 2023 | Feb 11, 2027phase 2 · NCT07215702 |
- Named in AstraZeneca’s own pipeline as
AZD4144
, phase 2, as of Oct 30, 2026 (source).
Also a collaborator on its studies: quotient-sciences and parexel.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 3, 2023First study: phase 1 study in Healthy ParticipantsFirst studyNCT06122714 · 95 enrolled · United States
- Jul 1, 2024Phase 1 study in Healthy ParticipantsNCT06491550 · 91 enrolled · United States
- Nov 4, 20242 phase 1 studiesNCT06675175, NCT06693765
- Apr 7, 20253 phase 1 studiesNCT06925854, NCT06942923, NCT06948006
- Oct 8, 2025Phase 2 study in SepsisNCT07215702 · 124 planned · United States, Argentina, Belgium and more
- Feb 10, 2026Phase 1 study in Healthy ParticipantsNCT07518459 · 16 enrolled · United Kingdom
- Jun 29, 2026Phase 1 study in HealthyNCT07685600 · 32 enrolled · United Kingdom
- Aug 20, 2026Phase 1 study in Hepatic ImpairmentNCT07783308 · 30 planned · United States
Ahead
- Feb 11, 2027Primary completion: phase 2 study in SepsisNCT07215702
- May 28, 2027Primary completion: phase 1 study in Hepatic ImpairmentNCT07783308
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07783308Hepatic Impairment · United States | 1 | Not yet recruiting | May 28, 2027 | 30 |
| NCT07685600Healthy · United Kingdom | 1 | Completed | Oct 22, 2026 | 32 |
| NCT07518459Healthy Participants · United Kingdom | 1 | Completed | May 26, 2026 | 16 |
| NCT07215702Sepsis · United States, Argentina, Belgium and more | 2 | Recruiting | Feb 11, 2027 | 124 |
| NCT06948006Healthy Participants · United Kingdom | 1 | Completed | Jun 27, 2025 | 32 |
| NCT06942923Atherosclerosis · Germany | 1 | Completed | Sep 29, 2025 | 28 |
| NCT06925854Inflammation · United Kingdom | 1 | Completed | Jun 12, 2025 | 12 |
| NCT06693765Renal Insufficiency · Bulgaria, Romania | 1 | Completed | Apr 23, 2025 | 41 |
| NCT06675175Renal Insufficiency, Chronic · United States, Bulgaria, Hungary and more | 1 | Completed | Oct 27, 2025 | 29 |
| NCT06491550Healthy Participants · United States | 1 | Completed | Jun 11, 2025 | 91 |
| NCT06122714Healthy Participants · United States | 1 | Completed | Dec 4, 2024 | 95 |
How it is read
Names in the registry
- “AZD4144”, 9 entries
- “[14C]AZD4144 Solution for Infusion”, 1 entry
- “[14C]AZD4144 Oral Solution”, 1 entry
- “AZD4144- Part A”, 1 entry
- “AZD4144- Part B”, 1 entry
Codes read as this program: AZD4144.
Conditions, from the studies’ own filings
- Sepsis, 1 study
- Kidney Failure, Chronic, 1 study
- Renal Insufficiency, Chronic, 1 study
- Atherosclerosis, 1 study
- Inflammation, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.